Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?
Mesenchymal stromal cells (MSC) have been used to treat a broad range of disease indications such as acute and chronic inflammatory disorders, autoimmune diseases, and transplant rejection due to their potent immunosuppressive/anti-inflammatory properties. The breadth of their usage is due in no sma...
Main Authors: | Paul Lohan, Oliver Treacy, Matthew D. Griffin, Thomas Ritter, Aideen E. Ryan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-11-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01626/full |
Similar Items
-
Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal Transplantation
by: Paul Lohan, et al.
Published: (2018-11-01) -
Subconjunctival administration of low-dose murine allogeneic mesenchymal stromal cells promotes corneal allograft survival in mice
by: Oliver Treacy, et al.
Published: (2021-04-01) -
Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight
by: Johannes Schetelig, et al.
Published: (2024-04-01) -
CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
by: Ariadna Bartoló-Ibars, et al.
Published: (2021-09-01) -
Donor and Recipient Individual Factors as Predictive Markers of Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation; Dream or Reality
by: Pooya Eslampour, et al.
Published: (2021-02-01)